Intraperitoneal Administration of Biointerface‐Camouflaged Upconversion Nanoparticles for Contrast Enhanced Imaging of Pancreatic Cancer

Abstract

Pancreatic cancer has one of the highest fatality rates of all diseases, but poor drug availability after intravenous (IV) administration has hindered the diagnosis and treatment of patients. Herein, the authors report a novel strategy, combining intraperitoneal administration and phosphatidylcholine‐camouflaged NaLuF4:Yb,Tm/NaLuF4/NaDyF4 upconversion nanoparticles (UCNP@PC) to gain the enhanced dual‐modal imaging (upconversion luminescence/magnetic resonance imaging) of orthotopic pancreatic cancer. Remarkably, the authors observe a 16‐fold improvement in the efficacy of utilization promoted intraperitoneally administered UCNP@PC in monitoring orthotopic pancreatic cancer compared with IV approach. Benefiting from modification with phosphatidylcholine, a major component of cell membranes, the optimized nanostructures show excellent biocompatibility and are rapidly excreted via the bile pathway after their intraperitoneal administration. The integration of the advanced design of UCNP@PC and the optimal drug administration route also give a general strategy for the advanced diagnosis and treatment of a series of intraperitoneal cancers.

Magnetic polymeric nanoassemblies for magnetic resonance imaging-combined cancer theranostics

“…They designed an NaDyF 4 :50% Lu@Prussian blue nanocomposite for T 1 -T 2weighted MRI, CT, and PTT with the help of the Prussian blue shell. 81 They also developed a UCL-T 2 dual-modal contrast agent with NaLuF 4 :Yb, Tm/NaLuF 4 /NaDyF 4 82 and a lanthanide-based core−shell−shell nanocomposite NaYbF 4 :Tm@CaF 2 @NaDyF 4 for upconversion MRI/CT multimodal imaging. 83 Liu et al 84 developed an Mn 3 O 4 contrast agent capped with EDTA and BSA for efficient T 1 -T 2 dual-modal imaging and PTT.…”

Multifunctional NaYF4:Nd/NaDyF4 nanocrystals as a multimodal platform for NIR-II fluorescence and magnetic resonance imaging

“…[42][43][44][45][46] Some rare earth elements (i.e., Gd 3+ and Dy 3+ ) as MRI contrast agents can be co-doped into upconversion NCs to achieve high tissue penetration depth utilizing multi-modal bioimaging. 12,47,48 Among them, Dy 3+ ions have the advantages of a short electron relaxation time ($0.5 ps) and large magnetic moment (10.6 m B ) and are considered to be an ideal contrast agent for T 2 -weighted MRI. 49 Dy 3+ doped upconversion NCs have been used as efficient T 2 -weighted contrast agents in ultrahigh eld MRI to obtain contrast enhancement.…”

Construction of a Dual Drug Carrier on the Basis of Hollow Structured Upconversion Nanoparticles for pH‐Responsive Drug Delivery and UCL/MRI Dual Mode Imaging

“…In addition, compared with normal FOI, upconversion luminescence imaging (UCL) can avoid the disturbance of autofluorescence background from biological tissues and organs, so it can help diagnose tumor more precisely . Therefore, to design a UCL/MRI dual mode imaging is meaningful to enhance the accuracy of diagnosis …”

“…[8][9][10] Therefore, to design a UCL/MRI dual mode imaging is meaningful to enhance the accuracy of diagnosis. [11][12][13] On the other hand, in order to improve the treatment efficiency of multifunctional drug carriers, it is necessary to reduce drug resistance and increase the precise release of drugs to cancer cells. In recent years, nanoparticles as drug carriers are widely studied in cancer therapy, but mostly are used for single drug.…”